Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Dr. Hamutal Meiri

Dr. Hamutal Meiri

Director Exploitation ASPRE Consortium Israel Israel

Hikmet Budak

Hikmet Budak

Professor, Montana State University, USA

Dr. Lihua Julie Zhu

Dr. Lihua Julie Zhu

Research Professor, University of Massachusetts Medical School USA

Dr. Muhsin Aydin

Dr. Muhsin Aydin

Researcher, Adiyaman University, Turkey

Halla Mohamed Ragab

Halla Mohamed Ragab

Professor, National Research Center, Egypt

CRISPR 2018

Invitation

Conferenceseries invites the contributors across the globe to participate in the premier “CRISPR Congress”, to discuss the theme: "CRISPR technology to feed, fuel and heal the world". The conference will be held in Boston, USA during October 19-20, 2018 wherein prompt keynote presentations, Oral talks, Poster presentations and Exhibitions are included.

“CRISPR” (pronounced “crisper”) stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology. In the field of genome engineering, the term “CRISPR” or “CRISPR-Cas9” is often used loosely to refer to the various CRISPR-Cas9 and -CPF1, (and other) systems that can be programmed to target specific stretches of genetic code and to edit DNA at precise locations, as well as for other purposes, such as for new diagnostic tools. With these systems, researchers can permanently modify genes in living cells and organisms and, in the future, may make it possible to correct mutations at precise locations in the human genome in order to treat genetic causes of disease. Other systems are now available, such as CRISPR-Cas13’s, that target RNA provide alternate avenues for use, and with unique characteristics that have been leveraged for sensitive diagnostic tools, such as SHERLOCK.

CRISPR genome editing allows scientists to quickly create cell and animal models, which researchers can use to accelerate research into diseases such as cancer and mental illness. In addition, CRISPR is now being developed as a rapid diagnostic.

Studies using in vitro (laboratory) and animal models of human disease have demonstrated that the technology can be effective in correcting genetic defects. Examples of such diseases include cystic fibrosis, cataracts and Fanconi anemia, according to a 2016 review article published in the journal Nature Biotechnology. These studies pave the way for therapeutic applications in humans.

CRISPR technology has also been applied in the food and agricultural industries to engineer probiotic cultures and to vaccinate industrial cultures (for yogurt, for example) against viruses. It is also being used in crops to improve yield, drought tolerance and nutritional properties.

One other potential application is to create gene drives. These are genetic systems, which increase the chances of a particular trait passing on from parent to offspring.

However, CRISPR-Cas9 is not without its drawbacks.

The genome-editing efficiencies can vary. According to the 2014 Science article by Doudna and Charpentier, in a study conducted in rice, gene editing occurred in nearly 50 percent of the cells that received the Cas9-RNA complex. Whereas, other analyses have shown that depending on the target, editing efficiencies can reach as high as 80 percent or more.

There is also the phenomenon of "off-target effects," where DNA is cut at sites other than the intended target. This can lead to the introduction of unintended mutations.

About Conference

International conference of CRISPR Congress is a Research-scientific knowledge bridge, that aims bring together multi-disciplinary luminaries for Thriving innovation in the Biotechnology. The scientific conferences have been carefully structured so as to share knowledge and thoughts through presentations and exhibitions. CRISPR Congress event with sessions covers all aspects of biotech-driven technique CRISPR and addresses the key issues currently affecting its researches. Attendees can look forward to hearing about the different strategies taken to improve ongoing research and decipher how to overcome technical limitations in research development. This conference is where pharm, investors and Life Science companies find partners, access innovation, find funding and brainstorm the solutions to further their business needs.

Target Audience:

Target Audience for CRISPR 2018 will be personnel from both industrial and academic fields which include; Directors/Managers, Head of Departmental, Presidents/Vice Presidents, CEO, Professors, Associate and Assistant professors, Research Scholars and students from the related fields.

Target Audience

Industry        40%

Academia     50%

Others          10%

Major Biotechnology Associations around the Globe:

 American Society for Biochemistry and Molecular Biology

 American Society of Gene Therapy

 European Federation of Biotechnology

 American Genetic Association

 Biotechnology and Biological Research Council (UK)

 European Association of Pharma Biotechnology

Sessions/Tracks

Sessions/Tracks:

Plant and Animal Biotechnology 

Agricultural biotechnology, also known as agritech, is an area of agricultural science involving the use of scientific tools and techniques, including genetic engineering, molecular markers, molecular diagnostics, vaccines, and tissue culture, to modify living organisms: plants, animals, and microorganisms. Biotechnology is used in many ways in agriculture. Agricultural biotechnology companies work to supply farmers with tools to increase the yield of plant and animal products, while lowering the costs of production. Agricultural biotechnology can also include production of plants such as orchids for ornamental purposes and plants that can be used for fuel production (biofuels). To accomplish these goals, biotechnologists develop products to protect animals and crops from disease and help farmers identify the best animals and seeds to use in selective breeding programs. Animal biotechnology is a branch of biotechnology in which molecular biology techniques are used to genetically engineer (i.e. modify the genome of) animals in order to improve their suitability for pharmaceutical, agricultural or industrial applications.

RELATED CONFERENCES:

Cell therapy and Molecular Medicine, September 27-28, 2017, Chicago, Illinois, USA;  Molecular Genetics and Gene Therapy, July 03-05, 2017 Thailand, Bangkok; Cell and Gene therapy, March 26-27, 2017 Berlin, Germany; 25th  World Congress on Cancer Therapy, Oct 18-20, 2017, Baltimore, USA; Stem Cell and Regenerative Medicine, September 25-26, 2017, Berlin, Germany; Wisconson Stem Cell Symposium, April 19, 2017, Wisconsin; Advances in Stem Cells and Regenerative Medicine, May 23 - 26, 2017, Heidelberg, Germany; Managing Cell and Human Identity, April 16, 2017, Pennsylvania, USA.

Cancer and stem cells

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cells—ectoderm, endoderm and mesoderm (see induced pluripotent stem cells)—but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.

RELATED CONFERENCES:

Stem Cell and Regenerative Medicine, September 25-26, 2017, Berlin, Germany;  Cell therapy and Molecular Medicine, September 27-28, 2017, Chicago, Illinois, USA; Cell Signaling and cancer Therapy, September 27-28, 2017, Chicago, Illinois,USA; ; Cancer therapy and Radiation oncology , August 28th, 29, 2017 Brussels, Belgium Tissue Engineering and Regenerative Medicine, August 23-24, 2017 San Francisco, California, USA; Wisconson Stem Cell Symposium, April 19, 2017, Wisconsin; 18th International Congress of Developmental Biology, June  18 - 22 , 2017, Singapore; Germinal Stem Cell Biology, June 18-23, 2017, Hong Kong, China; Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases, July 24-27, 2017, Vermont, Burlington, VT; Advances in Stem Cells and Regenerative Medicine, May 23 - 26, 2017, Heidelberg, Germany

Genome Editing Methods and Novel Tools

Genetic engineering is the manipulation of an organism's genome using biotechnology Principles. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species domains for the production of improved or novel organisms. Genetic engineering has applications in medicine, research, industry and agriculture and can be used on a wide range of plants, animals and micro organisms. Tissue engineering is the use of a integration of cellsengineering and materials principles, and suitable biochemical and physicochemical factors to improve or replace biological tissues. It involves the use of a scaffold for the formation of new viable tissue for a medical purpose. Tissue engineering cover a broad range of applications,  that repair or replace portions of or whole tissues (i.e., bonecartilageblood vesselsbladderskinmuscle etc.). The definition of regenerative medicine is often used same sense with tissue engineering, although those involved in regenerative medicine place more emphasis on the use of stem cells or progenitor cells to produce tissues.

RELATED CONFERENCES:

Cell therapy and Molecular Medicine, September 27-28, 2017, Chicago, Illinois, USA;  Molecular Genetics and Gene Therapy, July 03-05, 2017 Thailand, Bangkok; Cell and Gene therapy, March 26-27, 2017 Berlin, Germany; 25th  World Congress on Cancer Therapy, Oct 18-20, 2017, Baltimore, USA; Stem Cell and Regenerative Medicine, September 25-26, 2017, Berlin, Germany; Wisconson Stem Cell Symposium, April 19, 2017, Wisconsin; Advances in Stem Cells and Regenerative Medicine, May 23 - 26, 2017, Heidelberg, Germany; Managing Cell and Human Identity, April 16, 2017, Pennsylvania, USA.

Therapeutic Genome Editing 

Medical Biotechnology or Red Biotechnology is the use of living cells and cell materials to research and produce pharmaceutical and diagnostic products that help and prevent human diseases. Applications in pharmacology, gene therapy, stem cells, Tissue engineering. By discovering new drugs and vaccines, there have been improved and accelerated drug testing, better diagnostic capabilities, and the availability of foods which enhance nutritional values. It has applications in manufacture pharmaceuticals like enzymes, antibiotics and vaccines, and its use for molecular diagnostic. Today, the availability of “targeted therapies” for diseases and individuals should greatly improve drug safety and efficacy, and the development of predictive technologies may lead to a new era in disease prevention, especially in some of the world’s fast developing economies. This sound rationale holds great potential and promise in the field of medical biotechnology.

RELATED CONFERENCES:

Molecular Genetics and Gene Therapy, July03-05, 2017, Thailand, Bangkok; Human Genetics, September 14-15, 2017 Edinburgh, Scotland; Systems and Synthetic Biology, July 20-21, 2017 Munich, Germany; Integrative Biology, June 19-21, 2017, London, UK; Tissue Engineering and Regenerative Medicine, August 23-24 , 2017 San Francisco, California ,USA; Signal Transduction in the Immune System, June 18-23, 2017, Colorado, USA; The Tenth ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine, June 19-24, 2017, Dubrovnik, Croatia; Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology , March 19-23,2017, Whistler, Canada; Managing Cell and Human Identity, April 26, 2017, Philadelphia, U.S.

Genome editing and gene regulation in human health

“CRISPR” (pronounced “crisper”) stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology. In the field of genome engineering, the term “CRISPR” or “CRISPR-Cas9” is often used loosely to refer to the various CRISPR-Cas9 and -CPF1, (and other) systems that can be programmed to target specific stretches of genetic code and to edit DNA at precise locations, as well as for other purposes, such as for new diagnostic tools. With these systems, researchers can permanently modify genes in living cells and organisms and, in the future, may make it possible to correct mutations at precise locations in the human genome in order to treat genetic causes of disease. Other systems are now available, such as CRISPR-Cas13’s, that target RNA provide alternate avenues for use, and with unique characteristics that have been leveraged for sensitive diagnostic tools, such as SHERLOCK.

RELATED CONFERENCES:

Cell therapy and Molecular Medicine, September 27-28, 2017, Chicago, Illinois, USA;  Molecular Genetics and Gene Therapy, July 03-05, 2017 Thailand, Bangkok; Cell and Gene therapy, March 26-27, 2017 Berlin, Germany; 25th  World Congress on Cancer Therapy, Oct 18-20, 2017, Baltimore, USA; Stem Cell and Regenerative Medicine, September 25-26, 2017, Berlin, Germany; Wisconson Stem Cell Symposium, April 19, 2017, Wisconsin; Advances in Stem Cells and Regenerative Medicine, May 23 - 26, 2017, Heidelberg, Germany; Managing Cell and Human Identity, April 16, 2017, Pennsylvania, USA.

Genome editing and gene regulation in industrial bacterial biotechnology

CRISPR “spacer” sequences are transcribed into short RNA sequences (“CRISPR RNAs” or “crRNAs”) capable of guiding the system to matching sequences of DNA. When the target DNA is found, Cas9 – one of the enzymes produced by the CRISPR system – binds to the DNA and cuts it, shutting the targeted gene off. Using modified versions of Cas9, researchers can activate gene expression instead of cutting the DNA. These techniques allow researchers to study the gene’s function.

Research also suggests that CRISPR-Cas9 can be used to target and modify “typos” in the three-billion-letter sequence of the human genome in an effort to treat genetic disease.

RELATED CONFERENCES:

Molecular Genetics and Gene Therapy, July03-05, 2017, Thailand, Bangkok; Human Genetics, September 14-15, 2017 Edinburgh, Scotland; Systems and Synthetic Biology, July 20-21, 2017 Munich, Germany; Integrative Biology, June 19-21, 2017, London, UK; Tissue Engineering and Regenerative Medicine, August 23-24 , 2017 San Francisco, California ,USA; Signal Transduction in the Immune System, June 18-23, 2017, Colorado, USA; The Tenth ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine, June 19-24, 2017, Dubrovnik, Croatia; Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology , March 19-23,2017, Whistler, Canada; Managing Cell and Human Identity, April 26, 2017, Philadelphia, U.S.

Genome editing and gene regulation in industrial eukaryotic biotechnology

CRISPR-Cas9 is proving to be an efficient and customizable alternative to other existing genome editing tools. Since the CRISPR-Cas9 system itself is capable of cutting DNA strands, CRISPRs do not need to be paired with separate cleaving enzymes as other tools do. They can also easily be matched with tailor-made “guide” RNA (gRNA) sequences designed to lead them to their DNA targets. Tens of thousands of such gRNA sequences have already been created and are available to the research community. CRISPR-Cas9 can also be used to target multiple genes simultaneously, which is another advantage that sets it apart from other gene-editing tools.

RELATED CONFERENCES:

Tissue Engineering and Regenerative Medicine, August 23-24, 2017 San Francisco, California, USA; Tissue Preservation and Biobanking, August 23-24, 2017, San francisco, Californis, USA; Tissue Science and Regenerative Medicine, October 02-04, 2017 Barcelona, Spain; Solicitation of Proposals for the TERMIS-AM 2020 Conference, July 31, 2017

CRISPR technologies beyond genome editing and gene regulation

The genomes of various organisms encode a series of messages and instructions within their DNA sequences. Genome editing involves changing those sequences, thereby changing the messages. This can be done by inserting a cut or break in the DNA and tricking a cell's natural DNA repair mechanisms into introducing the changes one wants. CRISPR-Cas9 provides a means to do so.

In 2012, two pivotal research papers were published in the journals Science and PNAS, which helped transform bacterial CRISPR-Cas9 into a simple, programmable genome-editing tool. 

The studies, conducted by separate groups, concluded that Cas9 could be directed to cut any region of DNA. This could be done by simply changing the nucleotide sequence of crRNA, which binds to a complementary DNA target. In the 2012 Science article, Martin Jinek and colleagues further simplified the system by fusing crRNA and tracrRNA to create a single "guide RNA." Thus, genome editing requires only two components: a guide RNA and the Cas9 protein.

RELATED CONFERENCES:

Cell therapy and Molecular Medicine, September 27-28, 2017, Chicago, Illinois, USA;  Molecular Genetics and Gene Therapy, July 03-05, 2017 Thailand, Bangkok; Cell and Gene therapy, March 26-27, 2017 Berlin, Germany; 25th  World Congress on Cancer Therapy, Oct 18-20, 2017, Baltimore, USA; Stem Cell and Regenerative Medicine, September 25-26, 2017, Berlin, Germany; Wisconson Stem Cell Symposium, April 19, 2017, Wisconsin; Advances in Stem Cells and Regenerative Medicine, May 23 - 26, 2017, Heidelberg, Germany; Managing Cell and Human Identity, April 16, 2017, Pennsylvania, USA. 

Achieving efficient delivery and editing

CRISPR-Cas9 is proving to be an efficient and customizable alternative to other existing genome editing tools. Since the CRISPR-Cas9 system itself is capable of cutting DNA strands, CRISPRs do not need to be paired with separate cleaving enzymes as other tools do. They can also easily be matched with tailor-made “guide” RNA (gRNA) sequences designed to lead them to their DNA targets. Tens of thousands of such gRNA sequences have already been created and are available to the research community. CRISPR-Cas9 can also be used to target multiple genes simultaneously, which is another advantage that sets it apart from other gene-editing tools.

RELATED CONFERENCES:

Molecular Genetics and Gene Therapy, July03-05, 2017, Thailand, Bangkok; Human Genetics, September 14-15, 2017 Edinburgh, Scotland; Systems and Synthetic Biology, July 20-21, 2017 Munich, Germany; Integrative Biology, June 19-21, 2017, London, UK; Tissue Engineering and Regenerative Medicine, August 23-24 , 2017 San Francisco, California ,USA; Signal Transduction in the Immune System, June 18-23, 2017, Colorado, USA; The Tenth ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine, June 19-24, 2017, Dubrovnik, Croatia; Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology , March 19-23,2017, Whistler, Canada; Managing Cell and Human Identity, April 26, 2017, Philadelphia, U.S.

Horizons of CRISPR biology

CRISPR genome editing allows scientists to quickly create cell and animal models, which researchers can use to accelerate research into diseases such as cancer and mental illness. In addition, CRISPR is now being developed as a rapid diagnostic. To help encourage this type of research worldwide, scientists and their team have trained thousands of researchers in the use of CRISPR genome editing technology through direct education and by sharing more than 40,000 CRISPR components with academic laboratories around the world.

RELATED CONFERENCES:

Tissue Engineering and Regenerative Medicine, August 23-24, 2017 San Francisco, California, USA; Tissue Preservation and Biobanking, August 23-24, 2017, San francisco, Californis, USA; Tissue Science and Regenerative Medicine, October 02-04, 2017 Barcelona, Spain; Solicitation of Proposals for the TERMIS-AM 2020 Conference, July 31, 2017

CRISPR technologies and society

CRISPR-Cas9 has become popular in recent years. CRISPR technology has also been applied in the food and agricultural industries to engineer probiotic cultures and to vaccinate industrial cultures (for yogurt, for example) against viruses. It is also being used in crops to improve yield, drought tolerance and nutritional properties. There is also the phenomenon of "off-target effects," where DNA is cut at sites other than the intended target. This can lead to the introduction of unintended mutations.  Furthermore, Scientists noted that even when the system cuts on target, there is a chance of not getting a precise edit. They called this "genome vandalism."

RELATED CONFERENCES:

Stem Cell and Regenerative Medicine, September 25-26, 2017, Berlin, Germany;  Cell therapy and Molecular Medicine, September 27-28, 2017, Chicago, Illinois, USA; Cell Signaling and cancer Therapy, September 27-28, 2017, Chicago, Illinois,USA; ; Cancer therapy and Radiation oncology , August 28th, 29, 2017 Brussels, Belgium Tissue Engineering and Regenerative Medicine, August 23-24, 2017 San Francisco, California, USA; Wisconson Stem Cell Symposium, April 19, 2017, Wisconsin; 18th International Congress of Developmental Biology, June  18 - 22 , 2017, Singapore; Germinal Stem Cell Biology, June 18-23, 2017, Hong Kong, China; Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases, July 24-27, 2017, Vermont, Burlington, VT; Advances in Stem Cells and Regenerative Medicine, May 23 - 26, 2017, Heidelberg, Germany

Market Analysis

Biotechnology uses of biological processes in the development or manufacture of a product or in the technological solution to a problem. Since the discovery of DNA in 1953, and the identification of DNA as the genetic material in all life, there have been tremendous advances in the vast area of biotechnology. Biotech has a wide range of uses including food alterations, genetic research and cloning, human and animal health care, pharmaceuticals and the environment. The Global Biotechnology industry comprises a diverse range of companies engaged in the development of pharmaceuticals, pest-resistant crops and biofuels, among other products. Revenue for the industry has grown over the past five years and global investment in biotechnology has increased consistently, with much of the added R&D spending funneled into medical applications aimed at providing care for the aging global population. The Global Biotechnology industry is in the growth phase of its economic life cycle. Over the 10 years to 2021, revenue and industry value added (IVA) growth have outpaced world GDP growth. IVA, which measures the industry's contribution to the overall global economy, is forecast to grow 3.5% per year on average during the 10 years to 2021, slightly greater than annualized global GDP growth of 2.7% over the same period. The rapid increase in demand reflects the significant expansion in the products the industry supplies. Product lines increase as new technology is developed, processes are learned and products commercialized.

Biotechnology uses of biological processes in the development or manufacture of a product or in the technological solution to a problem. Since the discovery of DNA in 1953, and the identification of DNA as the genetic material in all life, there have been tremendous advances in the vast area of biotechnology. Biotech has a wide range of uses including food alterations, genetic research and cloning, human and animal health care, pharmaceuticals and the environment. The Global Biotechnology industry comprises a diverse range of companies engaged in the development of pharmaceuticals, pest-resistant crops and biofuels, among other products. Revenue for the industry has grown over the past five years and global investment in biotechnology has increased consistently, with much of the added R&D spending funneled into medical applications aimed at providing care for the aging global population. The Global Biotechnology industry is in the growth phase of its economic life cycle. Over the 10 years to 2021, revenue and industry value added (IVA) growth have outpaced world GDP growth. IVA, which measures the industry's contribution to the overall global economy, is forecast to grow 3.5% per year on average during the 10 years to 2021, slightly greater than annualized global GDP growth of 2.7% over the same period. The rapid increase in demand reflects the significant expansion in the products the industry supplies. Product lines increase as new technology is developed, processes are learned and products commercialized.

Total Revenue in Biotechnology and Annual growth:

The global biotechnology market size was valued at USD 270.5 billion in 2013 and is expected to grow at a CAGR of 12.3% owing to the increasing demand for diagnostics and therapeutics solutions such as recombinant technology, red biotechnology, and DNA sequencing. The increasing prevalence of diseases such as cancer, hepatitis B, and other orphan disorders is expected to serve as a high-impact rendering driver for this industry over the forecast period. Rising government initiatives owing to high significance towards growth of the economy are expected to boost the biotechnology market growth over the forecast period.

Increasing demand for agricultural and food products such as wheat, rice, sugarcane, and beans owing to growing population base in countries such as the U.S., China, and India is another major factor positively impacting the growth of the industry. Factors such as limited availability of agricultural land, shortage of water, the low yield of crops, and pest attacks are encouraging researchers to develop innovative agricultural technologies via extensive R&D activities. Application of biotechnological processes such as Genetic Modification (GM) and genetic engineering on agricultural products is a major driver for the growth of this industry.

Key technologies include fermentation, tissue engineering, nanobiotechnology, PCR technology, DNA sequencing, chromatography, cell-based assay, and others. In 2013, the tissue engineering and regeneration segment dominated the overall industry with USD 87.92 billion revenue. However, the DNA sequencing and cell-based assay segment is expected to witness lucrative growth till 2020 due to rising research and development initiatives by various pharmaceutical and biotechnological companies.

 DNA sequencing is expected to grow at a CAGR of over 18.1% owing to its wide applications in various verticals such as agriculture, biology, medical, and geology. Based on application, global biotechnology market is divided into biopharmaceutical, bioservices, bioagriculture, and bio industrial. In 2013, biopharmaceuticals that are segmented into advanced drugs, orphan drugs, monoclonal antibodies, and recombinant proteins dominated the overall industry with around USD 184.21 billion revenue. Asia Pacific is expected to gain substantial market share and reach around USD 145.9 billion by 2020. Escalating awareness about the advantages associated with adoption and introduction of healthcare benefits by the government are driving forces for this region. The market was dominated by Roche Diagnostics with a market share of 17.1% in 2013. Key strategies adopted by these companies to gain market share include strategic collaborations, mergers, outsourcing research & development, and manufacturing activities.

Past Conference Report

18th Biotechnology Congress 2017

Thanks to all of our Key Note Speakers, Organizing Committee members, honorable guests, wonderful speakers, conference attendees, Delegates and Media partners.

18th Biotechnology Congress 2017 Conference was the best!

18th Biotechnology Congress 2017 hosted by the Conference Series was held during October 19-20, 2017, Hilton New York JFK Airport Hotel New York, USA

 with the theme “Novel Insights and Innovations in Biotechnology for Leading a Better Life. Active participation was received from the scientists, engineers, researchers, students and leaders from the fields of Agricultural, Plant Biotechnology, Food Processing Safety and Processing, Pharmaceutical Biotechnology, Biomedical Engineering, Nano Biotechnology, Recycled Fuels, Biotechnology Industries in the Market who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

 Agricultural Biotechnology | Plant Biotechnology

 Food Processing Safety and Processing

 Pharmaceutical Biotechnology | Biomedical Engineering

 Nano Biotechnology | Recycled Fuels

 Biotechnology Industries in the Market | Biosafety and Bioethics

 Industrial Biotechnology | Bioprocess Engineering

The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list included:

  • Jeong-Woo Choi, Sogang University, South Korea
  • Andrea Nicolini, University of Pisa, Italy Peng Tian, Food and Drug Administration, USA
  • Fuad Fares, University of Haifa, Israel
  • Saikat Nandi, Cold Spring Harbor Laboratory, USA
  • Sima T. Tarzami, Howard University College of Medicine, USA
  • Julie M. Fagan, Rutgers University, New Jersey, USA
  • HeaYeon Lee, Mara Nanotech New York, inc., USA
  • Hiroshi Arakawa, IFOM - FIRC Institute of Molecular Oncology Foundation, Italy
  • Noriko Uchiyama, Takeda Pharmaceuticals International Co., USA
  •  

Conference Series offers its heartfelt appreciation to all the speakers who have attended and obliged to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. Conference Series also took privilege to felicitate the Organizing Committee Members who supported this event. We especially give a special thanks to moderator Dr Ana Rosu and poster presentation Judge Dr Fuad Fares. We give whole-hearted congratulation to our best poster winner.

To Collaborate Scientific Professionals around the World

Conference Date October 24-25, 2018

Speaker Opportunity

Past Conference Report

Supported By

Journal of Biotechnology & Biomaterials Advances in Genetic Engineering & Biotechnology Journal of Biodiscovery

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner